Crohn's Disease News and Research RSS Feed - Crohn's Disease News and Research

Crohn’s disease is a chronic inflammatory disease of the bowel affecting at least 115,000 people in the UK. The condition usually develops in teenagers and young adults, but can be diagnosed at any age and is equally common in men and women.

The condition can affect any part of the digestive tract between the mouth and the anus, although inflammation in the last section of the small bowel (ileum) or the first part of the large bowel (colon) is most common.

Crohn's disease is a ‘relapsing and remitting’ condition characterized by symptom-free periods followed by episodes of “flare-ups,” during which symptoms such as diarrhoea, abdominal pain, fever and fatigue may become particularly bothersome.

Long term, severe inflammation can damage sections of the digestive system, resulting in additional complications, such as a tear in the wall of the anus (fissure), narrowing of the intestine (stricture) or the formation of an abnormal connection between the bowel and another body part such as the bladder, vagina or skin (fistula). Such problems usually require surgical treatment to correct. Crohn's disease also increases the risk of developing bowel cancer.

The exact cause of Crohn's disease is not clear but experts believe a combination of factors may be at work including genetics, immune responses to certain bacteria or viruses and lifestyle factors such as diet or smoking status.
Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. [More]
Bacterial imbalance in the gut can lead to inflammation similar to Crohn's disease

Bacterial imbalance in the gut can lead to inflammation similar to Crohn's disease

Crohn's disease is one of a family of chronic inflammatory bowel diseases (IBD). While it has already been proven to have genetic causes, scientists have now shown that the presence of certain intestinal bacteria also plays a role. [More]
Study identifies gut immune system as new, effective target for diabetes

Study identifies gut immune system as new, effective target for diabetes

A commonly-used drug to treat inflammatory bowel disease, such as Crohn's disease, has been shown to lower blood sugar levels in obese mice, potentially identifying the gut immune system as a new and effective target in treating diabetes in humans. [More]
Minimally invasive laparoscopic surgery significantly lowers health care costs

Minimally invasive laparoscopic surgery significantly lowers health care costs

Adding to the clinical benefits and improved patient outcomes associated with minimally invasive surgery, Medtronic highlighted a study published in the March 25 online edition of JAMA Surgery. The new study demonstrated that patients who underwent laparoscopic colectomy procedures required fewer days of health care utilization and the health care system spent less on their acute and follow-up care than those who underwent traditional open surgery. [More]
Women with IBD may be at increased risk for developing cervical cancer

Women with IBD may be at increased risk for developing cervical cancer

Women with inflammatory bowel disease (IBD) may be at increased risk of cervical dysplasia and cancer, according to a new study1 published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Minimally-invasive surgery offers long-term cost savings for healthcare system, less trauma for patients

Minimally-invasive surgery offers long-term cost savings for healthcare system, less trauma for patients

Adding to the clinical benefits and improved patient outcomes associated with minimally-invasive surgery (MIS), Medtronic plc today highlighted new data demonstrating that patients who underwent minimally invasive colon resection procedures were able to leave the hospital faster, visit their doctors less for follow up care and take fewer medicines than those who underwent open surgery. [More]
Male genetic diversity declined due to wealth, power rather than `survival of fittest`

Male genetic diversity declined due to wealth, power rather than `survival of fittest`

The DNA you inherit from your parents contributes to the physical make-up of your body -- whether you have blue eyes or brown, black hair or red, or are male or female. [More]
Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. [More]
Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma

Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma

The objective of the survey was two-sided. On one side, we wanted to better understand needs, concerns and attitudes of people with UC in an effort to identify solutions to improve the management of the disease. On the other, we wanted to build a questionnaire that could be used by HCPs to help define patients’ needs and concerns. [More]
Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Raja Atreya wins award for novel diagnostic method to predict treatment outcomes in Crohn's disease

Professor Raja Atreya from Medical Clinic 1 of the Erlangen University Hospital has won the 60,000€ Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers for 2015. With his innovative diagnostic method, physicians can predict the clinical response of an expensive treatment of Crohn's disease which is associated with potential side effects. [More]
Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for SB2, its Remicade (Infliximab) biosimilar candidate, has been submitted to the European Medicines Agency (EMA). [More]
The Medical Minute highlights risk and symptoms of IBD in children

The Medical Minute highlights risk and symptoms of IBD in children

Occasional stomach aches are part of life. But when they continue for more than a few weeks, come back often or are accompanied by bloody stools and additional symptoms, the cause could be inflammatory bowel disease, or IBD. [More]
Young immigrants to Canada at greater risk of developing IBD

Young immigrants to Canada at greater risk of developing IBD

The younger a person is when they immigrate to Canada, the higher their risk of developing inflammatory bowel disease (IBD), and its major subtypes Crohn's disease and ulcerative colitis, according to a study by researchers at the University of Ottawa, the Institute for Clinical Evaluative Sciences and the Children's Hospital of Eastern Ontario. [More]
Key questions about colorectal cancer answered

Key questions about colorectal cancer answered

Colorectal cancer is the fourth most common cancer in the U.S., with more than 136,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years. [More]
Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen. [More]
Study finds racial disparities among children with Crohn's disease

Study finds racial disparities among children with Crohn's disease

A study published recently in the IBD Journal found significant differences in hospital readmissions, medication usage, and both medical and surgical complications of children with Crohn's disease related to race. In the study, black children had a 1.5 times higher frequency of hospital readmissions because of Crohn's disease compared to white children. [More]
Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Emulsifiers, which are added to most processed foods to aid texture and extend shelf life, can alter the gut microbiota composition and localization to induce intestinal inflammation that promotes the development of inflammatory bowel disease and metabolic syndrome, new research shows. [More]
Scientists find new links between inflammation and tissue regeneration

Scientists find new links between inflammation and tissue regeneration

Almost all injuries, even minor skin scratches, trigger an inflammatory response, which provides protection against invading microbes but also turns on regenerative signals needed for healing and injury repair - a process that is generally understood but remains mysterious in its particulars. [More]
Shire announces acquisition of Meritage Pharma

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones. [More]
InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference. [More]
Advertisement